Keene & Associates Inc. Reduces Stock Position in Pfizer Inc. (NYSE:PFE)

Keene & Associates Inc. lowered its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 15.1% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 95,073 shares of the biopharmaceutical company's stock after selling 16,929 shares during the period. Pfizer comprises about 2.0% of Keene & Associates Inc.'s portfolio, making the stock its 25th largest holding. Keene & Associates Inc.'s holdings in Pfizer were worth $2,522,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Good Life Advisors LLC increased its stake in shares of Pfizer by 27.1% in the 4th quarter. Good Life Advisors LLC now owns 71,410 shares of the biopharmaceutical company's stock valued at $1,895,000 after purchasing an additional 15,211 shares in the last quarter. Strata Wealth Advisors LLC increased its stake in Pfizer by 34.6% during the 4th quarter. Strata Wealth Advisors LLC now owns 15,162 shares of the biopharmaceutical company's stock worth $402,000 after buying an additional 3,897 shares in the last quarter. Convergence Investment Partners LLC increased its stake in Pfizer by 673.9% during the 4th quarter. Convergence Investment Partners LLC now owns 107,413 shares of the biopharmaceutical company's stock worth $2,850,000 after buying an additional 93,533 shares in the last quarter. Plan Group Financial LLC increased its stake in Pfizer by 14.3% during the 4th quarter. Plan Group Financial LLC now owns 35,789 shares of the biopharmaceutical company's stock worth $949,000 after buying an additional 4,472 shares in the last quarter. Finally, Allied Investment Advisors LLC increased its stake in Pfizer by 1.4% during the 4th quarter. Allied Investment Advisors LLC now owns 262,737 shares of the biopharmaceutical company's stock worth $6,970,000 after buying an additional 3,534 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Insider Buying and Selling at Pfizer

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the business's stock in a transaction dated Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now owns 27,707 shares of the company's stock, valued at $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.06% of the stock is owned by corporate insiders.

Pfizer Trading Up 1.6 %

NYSE PFE traded up $0.42 on Friday, reaching $26.32. The stock had a trading volume of 54,560,140 shares, compared to its average volume of 38,524,395. The firm has a market capitalization of $149.14 billion, a price-to-earnings ratio of 18.66, a P/E/G ratio of 0.64 and a beta of 0.64. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The stock has a fifty day moving average price of $26.30 and a two-hundred day moving average price of $27.42.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm's quarterly revenue was up 24.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.10 earnings per share. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be given a $0.43 dividend. This is a positive change from Pfizer's previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.54%. Pfizer's payout ratio is presently 121.99%.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the company. Bank of America reiterated a "neutral" rating and set a $29.00 price objective on shares of Pfizer in a research note on Tuesday, December 10th. StockNews.com cut Pfizer from a "strong-buy" rating to a "buy" rating in a report on Wednesday, November 20th. Wolfe Research initiated coverage on Pfizer in a report on Friday, November 15th. They set an "underperform" rating and a $25.00 target price on the stock. Citigroup lowered their target price on Pfizer from $30.00 to $29.00 and set a "neutral" rating on the stock in a report on Tuesday, January 28th. Finally, Evercore ISI upgraded Pfizer to a "strong-buy" rating in a report on Wednesday, October 30th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, Pfizer currently has a consensus rating of "Moderate Buy" and a consensus target price of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.